pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene is a pharma organization headquartered in Camana Bay, KY. Primary therapeutic focus areas include Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19, Ovarian Cancer, Carcinoma, Hepatoce
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
BGB DXP593
Phase 1 · small molecule · Covid19
BGB DXP593 for Covid19 is a Phase 1 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Internal code BGB-DXP593-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BeiGene
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Covid19
- Status
- completed
- Trials
- 1